Scholarlink

<p>This study aims to develop and optimize a baricitinib-loaded nanoemulgel for enhanced transdermal delivery in rheumatoid arthritis management. A nanoemulsion was optimized using the Box-Behnken design and incorporated into a Carbopol 980 gel base. The formulation was evaluated for in vitro release, ex vivo skin permeation, and in vivo anti-arthritic efficacy in a rat model. The optimized nanoemulgel showed a particle size of 77.12 ± 0.01&#xa0;nm, PDI of 0.225 ± 0.001, viscosity of 68,400 ± 12 cP, and spread ability of 8.7 ± 0.2&#xa0;g.cm/sec. It exhibited sustained drug release (81.6% in 24&#xa0;h), enhanced permeation (649.18&#xa0;µg/cm<sup>2</sup>), and significant in vivo anti-arthritic effects without dermal irritation. The nanoemulgel offers improved drug delivery and therapeutic outcomes, making it a promising candidate for rheumatoid arthritis treatment. Further clinical studies are needed.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and Characterization of Baricitinib Nanoemulgel with Antiarthritic Effect in Rats

  • 期刊论文

  • 发表日期：

    2025年3月31日

查看全文
  • Suhas Shivaji Siddheshwar,
  • Arti Changdev Ghorpade,
  • Someshwar Dattatraya Mankar,
  • Santosh Bhausaheb Dighe

摘要

This study aims to develop and optimize a baricitinib-loaded nanoemulgel for enhanced transdermal delivery in rheumatoid arthritis management. A nanoemulsion was optimized using the Box-Behnken design and incorporated into a Carbopol 980 gel base. The formulation was evaluated for in vitro release, ex vivo skin permeation, and in vivo anti-arthritic efficacy in a rat model. The optimized nanoemulgel showed a particle size of 77.12 ± 0.01 nm, PDI of 0.225 ± 0.001, viscosity of 68,400 ± 12 cP, and spread ability of 8.7 ± 0.2 g.cm/sec. It exhibited sustained drug release (81.6% in 24 h), enhanced permeation (649.18 µg/cm2), and significant in vivo anti-arthritic effects without dermal irritation. The nanoemulgel offers improved drug delivery and therapeutic outcomes, making it a promising candidate for rheumatoid arthritis treatment. Further clinical studies are needed.

Graphical Abstract